| 2024 |
Chan WY, Chua W, Wilkinson K, Epitakaduwa C, Mandaliya H, Descallar J, Roberts TL, Becker TM, Ng W, Lee CS, Lim SH-S, 'The Prognostic and Predictive Utility of CDX2 in Colorectal Cancer', INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 25 (2024) [C1]
Caudal type homeobox transcription factor 2 (CDX2) is a gastrointestinal cancer biomarker that regulates epithelial development and differentiation. Absence or low leve... [more]
Caudal type homeobox transcription factor 2 (CDX2) is a gastrointestinal cancer biomarker that regulates epithelial development and differentiation. Absence or low levels of CDX2 have been associated with poor prognosis and proposed as a chemotherapy response predictor. Tumour tissue samples from 668 patients with stage I¿IV colorectal cancer were stained for CDX2 and stratified into two subgroups according to expression levels. Statistical tests were used to evaluate CDX2's relationship with survival and chemotherapy response. Of 646 samples successfully stained, 51 (7.9%) had low CDX2 levels, and 595 (92.1%) had high levels. Low CDX2 staining was associated with poor differentiation and the presence of lymphovascular or perineural invasion and was more common in colon and right-sided tumours. Overall survival (p < 0.001) and disease-free survival (p = 0.009) were reduced in patients with low CDX2 expression. Multivariable analysis validated CDX2 as an independent poor prognostic factor after excluding confounding variables. There was no statistically significant improvement in survival with adjuvant chemotherapy in stage II colon cancer (p = 0.11). In the rectal cohort, there was no relationship between CDX2 levels and therapy response. While confirming the prognostic utility of CDX2 in colorectal cancer, our study highlights that larger studies are required to confirm its utility as a predictive chemotherapy biomarker, especially in left-sided and rectal cancers.
|
|
|
| 2022 |
Sridharan S, Day F, Loh J, Lynam J, Smart J, Holt B, Mandaliya H, Bonaventura A, Kumar M, Martin J, 'Phase I trial of hypofractionated chemoradiotherapy in the palliative management of esophageal and gastro-esophageal cancer', RADIATION ONCOLOGY, 17 (2022) [C1]
|
|
Open Research Newcastle |
| 2022 |
Day F, Sridharan S, Lynam J, Gedye C, Johnson C, Fraser A, Thompson SR, Michael M, Leong T, Roy A, Kumar M, van der Westhuizen A, Quah GT, Mandaliya H, Mallesara G, Sappiatzer J, Oldmeadow C, Martin J, 'Chemoradiotherapy with concurrent durvalumab for the palliative treatment of oligometastatic oesophageal and gastrooesophageal carcinoma with dysphagia: a single arm phase II clinical trial (PALEO, sponsored by the Australasian Gastro-Intestinal Trials Group)', BMC CANCER, 22 (2022)
|
|
|
| 2021 |
Navani V, Graves MC, Marchett GC, Mandaliya H, Bowden NA, Van Der Westhuizen A, 'Abstract 1672: Overall survival in metastatic melanoma correlates with pembrolizumab exposure and T cell exhaustion markers', Cancer Research, 81, 1672-1672 (2021)
|
|
|
| 2021 |
Navani V, Graves MC, Marchett GC, Mandaliya H, Bowden NA, van der Westhuizen A, 'Overall survival in metastatic melanoma correlates with pembrolizumab exposure and T cell exhaustion markers', PHARMACOLOGY RESEARCH & PERSPECTIVES, 9 (2021) [C1]
|
|
Open Research Newcastle |
| 2021 |
Travers A, Adler K, Blanchard G, Bonaventura T, Charlton J, Day F, Healey L, Kim S, Lombard J, Mallesara G, Mandaliya H, Navani V, Nordman I, Paterson R, Plowman L, Quah GT, Scalley M, Shrestha P, Tailor B, van der Westhuizen A, Zhang B, Gedye C, Lynam J, 'Business as unusual: medical oncology services adapt and deliver during COVID-19', INTERNAL MEDICINE JOURNAL, 51, 673-681 (2021) [C1]
Background: The COVID-19 pandemic has challenged cancer care globally, introducing resource limitations and competing risks into clinical practice. Aims: To describe th... [more]
Background: The COVID-19 pandemic has challenged cancer care globally, introducing resource limitations and competing risks into clinical practice. Aims: To describe the COVID-19 impact on medical oncology care provision in an Australian setting. Methods: Calvary Mater Newcastle and Newcastle Private Hospital medical oncology data from 1 February to 31 April 2019 versus 2020 were retrospectively analysed. Results: Three hundred and sixty-four inpatient admissions occurred in 2020, 21% less than in 2019. Total inpatient days decreased by 22% (2842 vs 2203). April was most impacted (36% and 44% fewer admissions and inpatient days respectively). Mean length of stay remained unchanged (6.4 vs 6.2 days, P = 0.7). In all, 5072 outpatient consultations were conducted, including 417 new-patient consultations (4% and 6% increase on 2019 respectively). Telephone consultations (0 vs 1380) replaced one-quarter of face-to-face consultations (4859 vs 3623, -25%), with minimal telehealth use (6 vs 69). Day Treatment Centre encounters remained stable (3751 vs 3444, -8%). The proportion of new patients planned for palliative treatment decreased (35% vs 28%, P = 0.04), observation increased (16% vs 23%, P¿=¿0.04) and curative intent treatment was unchanged (both 41%). Recruiting clinical trials decreased by one-third (45 vs 30), two trials were activated (vs 5 in 2019) and 45% fewer patients consented to trial participation (62 vs 34). Conclusion: Our medical oncology teams adapted rapidly to COVID-19 with significant changes to care provision, including fewer hospital admissions, a notable transition to telephone-based outpatient clinics and reduced clinical trial activity. The continuum of care was largely defended despite pandemic considerations and growing service volumes.
|
|
Open Research Newcastle |
| 2020 |
Ngo DTM, Williams T, Horder S, Kritharides L, Vardy J, Mandaliya H, Nordman IIC, Lynam J, Bonaventura T, Sverdlov AL, 'Factors Associated with Adverse Cardiovascular Events in Cancer Patients Treated with Bevacizumab', JOURNAL OF CLINICAL MEDICINE, 9 (2020) [C1]
|
|
Open Research Newcastle |
| 2020 |
Moth EB, Kiely BE, Martin A, Naganathan V, Della-Fiorentina S, Honeyball F, Zielinski R, Steer C, Mandaliya H, Ragunathan A, Blinman P, 'Older adults' preferred and perceived roles in decision-making about palliative chemotherapy, decision priorities and information preferences', JOURNAL OF GERIATRIC ONCOLOGY, 11, 626-632 (2020) [C1]
Aim: Patients with cancer have varied preferences for involvement in decision-making. We sought older adults' preferred and perceived roles in decision-making abou... [more]
Aim: Patients with cancer have varied preferences for involvement in decision-making. We sought older adults' preferred and perceived roles in decision-making about palliative chemotherapy; priorities; and information received and desired. Methods: Patients =65y who had made a decision about palliative chemotherapy with an oncologist completed a written questionnaire. Preferred and perceived decision-making roles were assessed by the Control Preferences Scale. Wilcoxon rank-sum tests evaluated associations with preferred role. Factors important in decision-making were rated and ranked, and receipt of, and desire for information was described. Results: Characteristics of the 179 respondents: median age 74y, male (64%), having chemotherapy (83%), vulnerable (Vulnerable Elders Survey-13 score = 3) (52%). Preferred decision-making roles (n = 173) were active in 39%, collaborative in 27%, and passive in 35%. Perceived decision-making roles (n = 172) were active in 42%, collaborative in 22%, and passive in 36% and matched the preferred role for 63% of patients. Associated with preference for an active role: being single/widowed (p = .004, OR = 1.49), having declined chemotherapy (p = .02, OR = 2.00). Ranked most important (n = 159) were "doing everything possible" (30%), "my doctor's recommendation" (26%), "my quality of life" (20%), and "living longer" (15%). A minority expected chemotherapy to cure their cancer (14%). Most had discussed expectations of cure (70%), side effects (88%) and benefits (82%) of chemotherapy. Fewer had received quantitative prognostic information (49%) than desired this information (67%). Conclusion: Older adults exhibited a range of preferences for involvement in decision-making about palliative chemotherapy. Oncologists should seek patients' decision-making preferences, priorities, and information needs when discussing palliative chemotherapy.
|
|
|
| 2020 |
Blanchard G, Bonaventura A, Dafters N, Day F, Gedye C, Gildenhuys J, Lombard JM, Lynam JF, Mallesara G, Nordman I, Van Der Westhuizen A, Mandaliya HA, 'The impact of integrating an oncology nurse practitioner into an acute care hospital emergency department: An Australian tertiary cancer centre experience.', Journal of Clinical Oncology, 38, e14029-e14029 (2020)
|
|
|
| 2019 |
Moth E, Kiely BE, Martin AJ, Naganathan V, Della-Fiorentina SA, Honeyball F, Zielinski R, Steer CB, Mandaliya HA, Ragunathan A, Blinman P, 'Older adults’ preferred and perceived roles in decision making about palliative chemotherapy: Their decision priorities, and information preferences.', Journal of Clinical Oncology, 37, 11546-11546 (2019)
|
|
|
| 2019 |
Mandaliya H, Jones M, Oldmeadow C, Nordman IIC, 'Prognostic biomarkers in stage IV non-small cell lung cancer (NSCLC): neutrophil to lymphocyte ratio (NLR), lymphocyte to monocyte ratio (LMR), platelet to lymphocyte ratio (PLR) and advanced lung cancer inflammation index (ALI)', TRANSLATIONAL LUNG CANCER RESEARCH, 8, 886-894 (2019) [C1]
Background: Currently, there is no single validated biomarker which can prognosticate survival in patients with stage IV non-small cell lung cancer (NSCLC). This study ... [more]
Background: Currently, there is no single validated biomarker which can prognosticate survival in patients with stage IV non-small cell lung cancer (NSCLC). This study examines the prognostic significance of four biomarkers: neutrophil to lymphocyte ratio (NLR), lymphocyte to monocyte ratio (LMR), platelet to lymphocyte ratio (PLR) and advanced lung cancer inflammation index (ALI) in patients with stage IV NSCLC. Methods: This study aimed to establish the relationship between NLR, LMR, PLR, ALI and overall survival (OS) at baseline and post first cycle of treatment using Cox univariate PH models. We also studied these biomarkers in the elderly (age =70 years). Clinical data was sourced from Calvary Mater Newcastle between 2010 and 2015. Results: Baseline NLR, PLR, LMR and ALI showed strong association with OS. Five unit increase in NLR and PLR was associated with an 11% and 0.5% increase in the hazard of death respectively while 1 unit increase in ALI resulted in 4% increase in hazard of death. Five unit increase in LMR was associated with a 50% reduction in hazard of death. Post-treatment NLR and low ALI correlated with shorter OS but no statistically significant relationship could be demonstrated for PLR nor LMR. Similar prognostic trends were noted for elderly. Conclusions: High NLR, high PLR, low LMR and low ALI at baseline are significantly associated with poor OS. High NLR and low ALI are significantly associated with poor OS post treatment. Findings are similar regardless of age.
|
|
Open Research Newcastle |
| 2017 |
Mandaliya H, Jones M, Oldmeadow C, Nordman I, '127P Prognostic significance of advanced lung cancer inflammation index (ALI) In untreated and treated stage IV non-small cell lung cancer (NSCLC): An Australian cancer centre experience', Annals of Oncology, 28 (2017)
|
|
|
| 2017 |
George M, Mandaliya H, Prawira A, 'A survey of medical oncology training in Australian medical schools: Pilot study', Jmir Medical Education, 3 (2017) [C1]
|
|
|
| 2017 |
Kumari N, Mandaliya HA, Evans T, McElduff P, Oldmeadow C, Day FL, 'Aspirin in the prevention of colorectal cancer recurrence.', Journal of Clinical Oncology, 35, 578-578 (2017)
|
|
|
| 2016 |
Mandaliya H, Nordman I, 'Metastatic Eccrine Porocarcinoma: A Rare Case of Successful Treatment', CASE REPORTS IN ONCOLOGY, 9, 454-456 (2016)
|
|
|
| 2016 |
Mandaliya H, Singh N, George S, George M, 'Choroid Melanoma Metastasis to Spine: A Rare Case Report', CASE REPORTS IN OPHTHALMOLOGICAL MEDICINE, 2016 (2016) [C1]
|
|
|
| 2016 |
Mandaliya H, Ansari Z, Evans T, Oldmeadow C, George M, 'Psychosocial analysis of cancer survivors in rural Australia: Focus on demographics, quality of life and financial domains', Asian Pacific Journal of Cancer Prevention, 17, 2459-2464 (2016) [C1]
Background: Cancer treatments can have long-term physical, psychological, financial, sexual and cognitive effects that may influence the quality of life. These can vary... [more]
Background: Cancer treatments can have long-term physical, psychological, financial, sexual and cognitive effects that may influence the quality of life. These can vary from urban to rural areas, survival period and according to the type of cancer. We here aimed to describe demographics and psychosocial analysis of cancer survivors three to five years post-treatment in rural Australia and also assess relationships with financial stress and quality of life domains. Materials and Methods: In this cross-sectional study, 65 participants visiting the outpatient oncology clinic were given a self-administered questionnaire. The inclusion criteria included three to five years post-treatment. Three domains were investigated using standardised and validated tools such as the Standard Quality of Life in Adult Cancer Survivors Scale (QLACS) and the Personal and Household Finances (HILDA) survey. Included were demographic parameters, quality of life, treatment information and well-being. Results: There was no evidence of associations between any demographic variable and either financial stress or cancer-specific quality of life domains. Financial stress was however significantly associated with the cancerspecific quality of life domains of appearance-related concerns, family related distress, and distress related to recurrence. Conclusions: This unique study effectively points to psychosocial aspects of cancer survivors in rural regions of Australia. Although the majority of demographic characteristics were not been found to be associated with financial stress, this latter itself is significantly associated with distress related to family and cancer recurrence. This finding may be of assistance in future studies and also considering plans to fulfil unmet needs.
|
|
Open Research Newcastle |
| 2016 |
Mandaliya H, Sung J, Hill J, Samali R, George M, 'Prostatakrebs: Fallberichte von seltenen Formen der Manifestation und Metastasierung', Kompass Onkologie, 3, 43-45 (2016)
|
|
|
| 2015 |
Mandaliya H, Sung J, Hill J, Samali R, George M, 'Prostate cancer: Cases of rare presentation and rare metastasis', Case Reports in Oncology, 8, 526-529 (2015)
|
|
|
| 2015 |
Mandaliya H, Baghi P, Prawira A, George MK, 'A Rare Case of Paclitaxel and/or Trastuzumab Induced Acute Hepatic Necrosis', CASE REPORTS IN ONCOLOGICAL MEDICINE, 2015 (2015)
|
|
|
| 2008 |
Prakash S, Chavda BV, Mandalia H, Dhawan R, Padmanabhan D, 'Headaches related to triptans therapy in patients of migrainous vertigo.', The journal of headache and pain, 9, 185-188 (2008)
|
|
|
